BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Citizens JMP has lowered its price target on Werewolf Therapeutics Inc. (NASDAQ:HOWL) to $3.00 from $4.00 while maintaining a Market Outperform rating on the stock. The company, currently trading at $1.24 with a market capitalization of $56.7 million, sits well below the broader analyst target range of $4-$12.
The price target reduction was announced on Thursday as Citizens JMP analyst Reni Benjamin updated the firm’s outlook based on a platform value and cash/share analysis.
Werewolf Therapeutics recently reported its second quarter 2025 financial results and announced the selection of its first CD3-masked T-cell engager (TCE) development candidate targeting STEAP1.
The company maintains a partnership with Jazz Pharma and reported a cash position of $77.6 million, according to the analyst note.
Citizens JMP noted that important data updates for Werewolf Therapeutics are expected in the fourth quarter of 2025, which factored into the firm’s continued Market Outperform rating despite the reduced price target. The company’s next earnings report is scheduled for November 6, 2025. For deeper insights into HOWL’s financial health and additional analysis, check out the comprehensive research report available on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.